Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Med ; 11(22): 4354-4365, 2022 11.
Article in English | MEDLINE | ID: mdl-35638719

ABSTRACT

BACKGROUND: There is substantial variability in prostate cancer (PCa) mortality rates across Caucasian American (CA), African American (AA), Asian, and Hispanic men; however, these estimates are unable to disentangle race or ethnicity from confounding factors. The current study explores survival differences in long-term PCa outcomes between self-reported AA and CA men, and examines clinicopathologic features across self-reported CA, AA, Asian, and Hispanic men. METHODS: This retrospective cohort study utilized the Center for Prostate Disease Research (CPDR) Multi-center National Database from 1990 to 2017. Subjects were consented at military treatment facilities nationwide. AA, CA, Asian, or Hispanic men who underwent radical prostatectomy (RP) for localized PCa within the first year of diagnosis were included in the analyses. Time from RP to biochemical recurrence (BCR), BCR to metastasis, and metastasis to overall death were evaluated using Kaplan-Meier unadjusted estimation curves and adjusted Cox proportional hazards regression. RESULTS: This study included 7067 men, of whom 5155 (73%) were CA, 1468 (21%) were AA, 237 (3%) were Asian, and 207 (3%) were Hispanic. AA men had a significantly decreased time from RP to BCR compared to CA men (HR = 1.25, 95% CI = 1.06-1.48, p = 0.01); however, no difference was observed between AA and CA men for a time from BCR to metastasis (HR = 0.73, 95% CI = 0.39-1.33, p = 0.302) and time from metastasis to overall death (HR = 0.67, 95% CI = 0.36-1.26, p = 0.213). CONCLUSIONS: In an equal access health care setting, AA men had a shorter survival time from RP to BCR, but comparable survival time from BCR to metastasis and metastasis to overall death.


Subject(s)
Military Health , Prostatic Neoplasms , Male , Humans , Retrospective Studies , Neoplasm Recurrence, Local/pathology , Prostatic Neoplasms/pathology , Prostatectomy , Prostate-Specific Antigen , Cohort Studies
2.
Proc Natl Acad Sci U S A ; 104(15): 6406-11, 2007 Apr 10.
Article in English | MEDLINE | ID: mdl-17379666

ABSTRACT

Circadian rhythms and the genes that make up the molecular clock have long been implicated in bipolar disorder. Genetic evidence in bipolar patients suggests that the central transcriptional activator of molecular rhythms, CLOCK, may be particularly important. However, the exact role of this gene in the development of this disorder remains unclear. Here we show that mice carrying a mutation in the Clock gene display an overall behavioral profile that is strikingly similar to human mania, including hyperactivity, decreased sleep, lowered depression-like behavior, lower anxiety, and an increase in the reward value for cocaine, sucrose, and medial forebrain bundle stimulation. Chronic administration of the mood stabilizer lithium returns many of these behavioral responses to wild-type levels. In addition, the Clock mutant mice have an increase in dopaminergic activity in the ventral tegmental area, and their behavioral abnormalities are rescued by expressing a functional CLOCK protein via viral-mediated gene transfer specifically in the ventral tegmental area. These findings establish the Clock mutant mice as a previously unrecognized model of human mania and reveal an important role for CLOCK in the dopaminergic system in regulating behavior and mood.


Subject(s)
Bipolar Disorder/genetics , Circadian Rhythm/genetics , Trans-Activators/genetics , Analysis of Variance , Animals , Behavioral Symptoms/genetics , Bipolar Disorder/drug therapy , Bipolar Disorder/pathology , Bipolar Disorder/therapy , CLOCK Proteins , Electric Stimulation , Gene Expression Regulation/genetics , Gene Transfer Techniques , Genetic Therapy/methods , Glycogen Synthase Kinase 3/genetics , Glycogen Synthase Kinase 3 beta , Immunohistochemistry , Lithium/pharmacology , Lithium/therapeutic use , Lithium Compounds/pharmacology , Lithium Compounds/therapeutic use , Locomotion/drug effects , Mice , Mutagenesis , Mutation/genetics , Trans-Activators/therapeutic use , Ventral Tegmental Area/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...